Aarti Drugs Ltd

Meeting Details

• Board meeting scheduled for Thursday, August 27, 2026 (time and venue not disclosed).

Key Agenda Items

• Consider and approve the Performance Stock Option Plan 2026 and related matters.

Other Notes

• Trading window closed from August 25 to 29, 2026.

Meeting Details

• Date & time: 20 Aug 2026, 1:00 PM–6:00 PM; 1x1/group meeting; organized by Systematix; venue Mumbai.

Participants

• Company officials (management) to participate in investor meetings.

Purpose

• Discussions based on publicly available information; no UPSI to be discussed.

Litigation update

• Supreme Court of India dismissed the GST Department's Special Leave Petition.
• Dispute relates to IGST/CGST demand for FY2017-18 to FY2021-22; Bombay High Court order set aside.
• No material financial impact; company states no effect on operations.
• Status: matter disposed; no further action required.
• Original disclosure issued March 16, 2026; SLP outcome confirmed August 10, 2026.

Meeting Details

• Date: August 3, 2026; Time: not disclosed
• Type/Mode: Group earnings conference call, virtual listen-only with Q&A
• Event/Organizer: Q1 FY27 Earnings Conference Call by Aarti Drugs Limited

Participants

• Company management: Chief Operating Officer and Chief Financial Officer
• Company management: Joint Managing Director
• Company management: Whole-Time Director

Purpose

• Discuss Q1 FY27 earnings results and performance
• Provide updates on regulatory approvals and capacity expansion

Additional Notes

• Transcript available for Q1 FY27 Earnings Call
• Audio recording uploaded to stock exchanges
• Investor presentation uploaded on stock exchanges and company website

Leadership changes

• Board approves elevating Rashesh C. Gogri to Chairman in addition to MD, effective Oct 1, 2026.
• Adhish P. Patil appointed Managing Director, subject to shareholders' approval at the AGM.
• Prakash M. Patil to retire as Chairman, MD & CEO, effective Sep 30, 2026.
• Adhish P. Patil currently CFO since 2014 will assume MD responsibilities.

Strategic rationale

• Transition aims to strengthen governance and support long-term growth.
• Leadership realignment preserves institutional knowledge while enabling faster execution across operations.
• Leadership transition does not alter long-term strategic direction.

Director / KMP changes

• Retirement: Shri Prakash M. Patil to resign as Chairman, MD and CEO, Sep 30, 2026.
• Appointment: Shri Rashesh C. Gogri elevated to Chairman effective Oct 1, 2026.
• Appointment: Shri Adhish P. Patil appointed MD 5 years from Oct 1, 2026 (shareholders' approval).
• Appointment: Shri Nilesh B. Patil appointed Whole-time Director 5-year term from AGM conclusion.
• Retirement: Shri Uday M. Patil retires by rotation and is not offered re-appointment.
• Re-appointment: Shri Harshit M. Savla re-appointed Joint Managing Director for 5 years from Jun 1, 2027.
• Re-appointment: Shri Harit P. Shah re-appointed Whole-time Director for 5 years from Jun 1, 2027.
• Re-appointment: Shri Hasmukh B. Dedhia re-appointed Independent Director for 5-year term from Mar 29, 2027.
• Re-appointment: Shri Ajit E. Venugopalan re-appointed Independent Director for 5-year term from Mar 29, 2027.
• Re-appointment: Shri Sandeep M. Joshi re-appointed Independent Director for 5-year term from Mar 29, 2027.
• Profile: Nilesh B. Patil has 33+ years with B.Com and MBA HRM.
• Profile: Adhish P. Patil has 21 years in manufacturing operations, finance, regulatory compliance.
• Relation: Adhish P. Patil is son of Prakash P. Patil.
• Promoter: Harshit M. Savla is a promoter director.
• Promoter group: Rashesh C. Gogri and Adhish P. Patil belong to promoter group.
• Audit Committee reconstituted; Dedhia as Independent Chair.
• Nomination & Remuneration Committee reconstituted; Neha Gada as Chair.
• Risk Management Committee reconstituted; Rashesh Gogri as MD Chair.
• CSR Committee reconstituted; Bhaskar Thorat as Chair.
• Finance & Investment Committee reconstituted; Rashesh Gogri as Chair.
• Committees reconstituted with effect Oct 1, 2026.
• Not debarred: None of the above persons are debarred.

Financial results approved

• Audited standalone and consolidated results for quarter ended 30 June 2026 approved.

Audit and regulatory status

• Audit Committee reviewed and Board approved the results on 31 July 2026.
• Statutory auditors expressed unmodified opinion on the quarter ended 30 June 2026.

Publication and dissemination

• Results to be published in newspapers under Regulation 47.
• Results will be uploaded on the company website and on BSE/NSE.

Company structure

• As of 30 June 2026, three subsidiaries and two step-down subsidiaries.

Operational notes

• Company operates a single pharmaceutical segment.

Exceptional items

• Exceptional item: write-off of CWIP of Rs 2.09 crore for administrative building.

Meeting Details

• Date and time: August 3, 2026 at 11:00 AM IST.
• Group earnings call; virtual conference.
• Organizer: Strategic Growth Advisors Pvt. Ltd.
• Event: Q1 FY27 Earnings Conference Call.

Participants

• Key company participants: Jt. Managing Director; Whole Time Director; CFO & COO; MD, Pinnacle Life Science Private Limited.

Purpose

• Purpose: earnings results discussion with investors and analysts.

Additional Notes

• Pre-registration link available for attendees.

Dematerialisation processing status

• Dematerialisation requests processed and confirmed to the depositories.
• Securities dematerialised have been listed on the exchanges where earlier issues are listed.
• Physical certificates for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within timelines.